BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Pharm Country

  Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program

  ARV-378 is an orally bioavailable small molecule PROTAC designed to target and induce the degradation of the estrogen receptor protein, which plays a prominent role in the development of ER positive breast cancer.

  December 20, 2017

   · 

  2 min read
• 

  Deals

  MilliporeSigma, bluebird bio Forge Deal for Viral Vector Manufacturing

  MilliporeSigma today announced that it has signed a commercial supply agreement to manufacture viral vectors for bluebird bio for its use in potentially transformative gene therapies.

  December 20, 2017

   · 

  4 min read
• 

  Business

  Juno, Thermo Fisher Ink CAR T Manufacturing Partnership

  Under the seven-year nonexclusive licensing and supply agreement, Juno has obtained rights to use CTS Dynabeads CD3/CD28 magnetic beads as part of the clinical and commercial manufacturing processes for its current and future CAR T therapies.

  December 20, 2017

   · 

  4 min read
• BioMidwest

  Aratana Therapeutics Granted Conditional License for a Canine Osteosarcoma Therapeutic

  Aratana today announced the USDA Center for Veterinary Biologics granted Aratana conditional licensure for Canine Osteosarcoma Vaccine, Live Listeria Vector for the treatment of dogs diagnosed with osteosarcoma, one year of age or older.

  December 20, 2017

   · 

  8 min read
• Pharm Country

  Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes

  The exchange is expected to close on Friday, December 22, 2017, subject to customary closing conditions.

  December 20, 2017

   · 

  5 min read
• Business

  Selexis SA and Turgut Pharmaceuticals Advance Partnership With Third Commercial License Agreement

  The new agreement builds on two commercial license agreements established between the companies in July 2016 to develop biosimilar products to treat inflammatory diseases and certain cancers using the SURE CHO-M Cell Lines.

  December 20, 2017

   · 

  5 min read
• Biotech Bay

  Savonix to Present at Digital Medicine and Medtech Showcase 2018

  Savonix announced that Dr. Mylea Charvat, CEO and Founder, will present at the Digital Medicine & Medtech Showcase ™ 2018 Conference to be held January 8-10, 2018 in San Francisco, CA.

  December 20, 2017

   · 

  2 min read
• 

  Deals

  Millendo Therapeutics Sweeps Up Phase II Asset With Acquisition of Small Biotech

  Millendo Therapeutics announced that it has acquired Alize Pharma SAS in a stock-based transaction.

  December 20, 2017

   · 

  5 min read
• 

  Drug Development

  Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties

  Bone Biologics announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model.

  December 20, 2017

   · 

  1 min read
• Drug Development

  Peloton Therapeutics Phase I Study of PT2385 Published in the Journal of Clinical Oncology Validates HIF-2α Antagonism for the Treatment of Kidney Cancer

  These data demonstrated PT2385, the first clinical stage antagonist of hypoxia inducible factor-2α (HIF-2α), has a favorable safety profile and is active in patients with heavily pretreated clear cell renal cell carcinoma (ccRCC).

  December 20, 2017

   · 

  5 min read